Hansen Wong

880 total citations
27 papers, 570 citations indexed

About

Hansen Wong is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Hansen Wong has authored 27 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Hematology. Recurrent topics in Hansen Wong's work include CAR-T cell therapy research (9 papers), Ubiquitin and proteasome pathways (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Hansen Wong is often cited by papers focused on CAR-T cell therapy research (9 papers), Ubiquitin and proteasome pathways (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Hansen Wong collaborates with scholars based in United States, Germany and Australia. Hansen Wong's co-authors include D.C. Liebler, Sharon E. Murphy, Stephen S. Hecht, Ying Fang, Zhengping Wang, Jing Jiang, Mark K. Bennett, Jinfu Yang, Christopher J. Kirk and Christopher J. Molineaux and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Hansen Wong

25 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hansen Wong United States 13 348 198 189 79 52 27 570
Wen‐Hsing Lin Taiwan 19 569 1.6× 260 1.3× 111 0.6× 37 0.5× 46 0.9× 45 987
Xavier Billot Canada 7 463 1.3× 152 0.8× 57 0.3× 40 0.5× 55 1.1× 10 769
Michael W. Lago United States 10 209 0.6× 93 0.5× 161 0.9× 34 0.4× 17 0.3× 13 538
Carol Hartke United States 11 295 0.8× 237 1.2× 71 0.4× 104 1.3× 32 0.6× 13 638
Peter D. Gorycki United States 13 344 1.0× 166 0.8× 47 0.2× 116 1.5× 24 0.5× 29 735
Malkhey Verma India 15 430 1.2× 99 0.5× 70 0.4× 27 0.3× 31 0.6× 43 700
Xiaoying Lan China 15 461 1.3× 227 1.1× 95 0.5× 15 0.2× 34 0.7× 20 699
Henrik Möbitz Switzerland 17 551 1.6× 134 0.7× 67 0.4× 18 0.2× 33 0.6× 26 833
Emile G. Plise United States 17 493 1.4× 312 1.6× 27 0.1× 115 1.5× 56 1.1× 39 876
Crescent R. Isham United States 10 354 1.0× 255 1.3× 41 0.2× 18 0.2× 70 1.3× 14 686

Countries citing papers authored by Hansen Wong

Since Specialization
Citations

This map shows the geographic impact of Hansen Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hansen Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hansen Wong more than expected).

Fields of papers citing papers by Hansen Wong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hansen Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hansen Wong. The network helps show where Hansen Wong may publish in the future.

Co-authorship network of co-authors of Hansen Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Hansen Wong. A scholar is included among the top collaborators of Hansen Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hansen Wong. Hansen Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Wenhui, Dorothy Cheung, Alice Fong, et al.. (2025). Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies. Clinical and Translational Science. 18(10). e70338–e70338.
2.
Moschos, Stergios J., Shahneen Sandhu, Karl D. Lewis, et al.. (2022). Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Investigational New Drugs. 40(5). 1051–1065. 9 indexed citations
3.
Papayannidis, Cristina, Erika Borlenghi, David T Yeung, et al.. (2022). A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 40(16_suppl). e19003–e19003. 2 indexed citations
4.
5.
6.
Martínez‐Sánchez, Pilar, Paul Gordon, Stefan Schwartz, et al.. (2021). Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL). Blood. 138(Supplement 1). 2303–2303. 7 indexed citations
7.
Rossi, Giuseppe, H. Miles Prince, Constantine S. Tam, et al.. (2021). A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL). Blood. 138(Supplement 1). 2436–2436. 5 indexed citations
8.
9.
Wang, Zhican, Ying Fang, Juli Teague, et al.. (2017). In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s. Drug Metabolism and Disposition. 45(7). 712–720. 18 indexed citations
10.
Tchao, Nadia K., et al.. (2017). Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells. Blood. 130(Suppl_1). 696–696. 17 indexed citations
11.
Federspiel, Joel D., Simona G. Codreanu, Sandeep Goyal, et al.. (2016). Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells. Molecular & Cellular Proteomics. 15(10). 3233–3242. 24 indexed citations
12.
Infante, Jeffrey R., David S. Mendelson, Howard A. Burris, et al.. (2016). A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Investigational New Drugs. 34(2). 216–224. 49 indexed citations
13.
Shain, Kenneth H., Peter M. Voorhees, Nashat Gabrail, et al.. (2015). Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study. Clinical Lymphoma Myeloma & Leukemia. 15. e273–e273. 5 indexed citations
14.
15.
Savona, Michael R., Jesús G. Berdeja, Sang Hyuck Lee, et al.. (2012). A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies. Blood. 120(21). 203–203. 7 indexed citations
16.
Yang, Jinfu, Zhengping Wang, Ying Fang, et al.. (2011). Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats. Drug Metabolism and Disposition. 39(10). 1873–1882. 110 indexed citations
17.
Papadopoulos, Kyriakos P., David S. Mendelson, A. W. Tolcher, et al.. (2011). A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3075–3075. 19 indexed citations
18.
Papadopoulos, K., David S. Mendelson, A. W. Tolcher, et al.. (2011). 1209 POSTER ONX 0912, a Novel Oral Proteasome Inhibitor (PI), in Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study. European Journal of Cancer. 47. S147–S147. 1 indexed citations
19.
Wong, Hansen, Sharon E. Murphy, & Stephen S. Hecht. (2004). Cytochrome P450 2A-Catalyzed Metabolic Activation of Structurally Similar Carcinogenic Nitrosamines:  N‘-Nitrosonornicotine Enantiomers, N-Nitrosopiperidine, and N-Nitrosopyrrolidine. Chemical Research in Toxicology. 18(1). 61–69. 78 indexed citations
20.
Wong, Hansen, Sharon E. Murphy, & Stephen S. Hecht. (2003). Preferential Metabolic Activation of N-Nitrosopiperidine as Compared to Its Structural Homologue N-Nitrosopyrrolidine by Rat Nasal Mucosal Microsomes. Chemical Research in Toxicology. 16(10). 1298–1305. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wen‐Hsing Lin Breakdown of academic impact, for papers by Xavier Billot Breakdown of academic impact, for papers by Michael W. Lago Breakdown of academic impact, for papers by Carol Hartke Breakdown of academic impact, for papers by Peter D. Gorycki Breakdown of academic impact, for papers by Malkhey Verma Breakdown of academic impact, for papers by Xiaoying Lan Breakdown of academic impact, for papers by Henrik Möbitz Breakdown of academic impact, for papers by Emile G. Plise Breakdown of academic impact, for papers by Crescent R. Isham
Rankless by CCL
2026